Esperion (ESPR) ntered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs. This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents. Pursuant to the agreement, Micro Labs has agreed not to market a generic version of NEXLETOL in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion’s Strategic Expansion and Promising Financial Outlook Earns Buy Rating
- Esperion enters license and distribution agreement with HLS Therapeutics
- Esperion Therapeutics Reports Mixed Q1 2025 Results
- Esperion Therapeutics Reports Strong Q1 2025 Earnings
- Esperion’s Growth Potential: Buy Rating Affirmed Amid Strong Sales and Strategic Advances